<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HF9C23D3C960842AF9B82E5C70D035BE9" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 1537 IH: Advancing Hope Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-03-23</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 1537</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150323">March 23, 2015</action-date>
			<action-desc><sponsor name-id="B001251">Mr. Butterfield</sponsor> (for himself, <cosponsor name-id="M001157">Mr. McCaul</cosponsor>, <cosponsor name-id="V000128">Mr. Van Hollen</cosponsor>, <cosponsor name-id="K000376">Mr. Kelly of Pennsylvania</cosponsor>, and <cosponsor name-id="C001068">Mr. Cohen</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Federal Food, Drug, and Cosmetic Act to reauthorize a program of priority review to
			 encourage treatments for rare pediatric diseases, and for other purposes.</official-title>
	</form>
	<legis-body id="HA9B9C854FE3F47C1991FE8AF193208F9" style="OLC">
 <section id="HE1472A6D56824531AA54C668575B126E" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Advancing Hope Act of 2015</short-title></quote>.</text> </section><section id="H2CFA4588C23F465298310C110D905BF0"><enum>2.</enum><header>Reauthorization of program for priority review To encourage treatments for rare pediatric diseases</header><text display-inline="no-display-inline">Section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>) is amended—</text>
 <paragraph id="HCFE3C1205292422BBF70078BB6CD77F7"><enum>(1)</enum><text>in subsection (a)—</text> <subparagraph id="H88EF544487D44F319A52FC0FFBB867B1"><enum>(A)</enum><text>by amending paragraph (3) to read as follows:</text>
					<quoted-block display-inline="no-display-inline" id="H3A2D2BEA948248DB9BC4D18F8F043A86" style="OLC">
 <paragraph id="H24C57B52D45742B3BEA806822C81F04C"><enum>(3)</enum><header>Rare pediatric disease</header><text display-inline="yes-display-inline">The term <term>rare pediatric disease</term> means any of the following:</text> <subparagraph id="H0D212EB19C104CBFA2D3BC8BCA968045"><enum>(A)</enum><text>A disease that meets each of the following criteria:</text>
 <clause id="HACBA42B933DC4D85AF8E459471DD306F"><enum>(i)</enum><text>The disease primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.</text>
 </clause><clause id="H833937090A594F74B07F743588A93AE1"><enum>(ii)</enum><text>The disease is a rare disease or condition, within the meaning of section 526.</text> </clause></subparagraph><subparagraph id="HA0CE2DBBDC42498DAF582D992ADC8C06"><enum>(B)</enum><text display-inline="yes-display-inline">Any form of sickle cell disease.</text>
 </subparagraph><subparagraph id="H266C3CFA0EE14D6F9D94B32C230BB1EA"><enum>(C)</enum><text>Any pediatric cancers.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block> </subparagraph><subparagraph id="H58F87CD33F19497BB7203842E97FFCD8"><enum>(B)</enum><text>in paragraph (4)(A)—</text>
 <clause id="H102DF4FE1C0E49C38D71B0F6AFCDD45C"><enum>(i)</enum><text>in subparagraph (E), by striking <quote>and</quote> at the end;</text> </clause><clause id="H76EAA181A57A45668ADC45A62B67C809"><enum>(ii)</enum><text>in subparagraph (F), by striking the period at the end and inserting <quote>; and</quote>; and</text>
 </clause><clause id="H4779EDE79D1D4F96AFB66355A77FEE3F"><enum>(iii)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H9639375A41664CCCA483E38FE5A6AEB8" style="OLC"> <subparagraph id="H5A62205E8A1442FBB8E649B861D892A1"><enum>(G)</enum><text display-inline="yes-display-inline">is for a drug or biological product for which a priority review voucher has not been issued under section 524 (relating to tropical disease products).</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </clause></subparagraph></paragraph><paragraph id="HA028EAB934644866851E576F8C8BF8CB"><enum>(2)</enum><text>in subsection (b), by striking paragraph (5).</text> </paragraph></section><section id="HA4D7B0C8769243B7B16871DF1DBED96D"><enum>3.</enum><header>Limitation on priority review vouchers for tropical disease products</header><text display-inline="no-display-inline">Subparagraph (A) of section 524(a)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360n">21 U.S.C. 360n(a)(4)</external-xref>) is amended—</text>
 <paragraph id="HB02F69BB7C774C84B9F0719B6879EE3C"><enum>(1)</enum><text>in clause (i), by striking <quote>and</quote> at the end;</text> </paragraph><paragraph id="HAD840760B7954918BF3C0CF875AA1C46"><enum>(2)</enum><text>in clause (ii), by inserting <quote>and</quote> at the end; and</text>
 </paragraph><paragraph id="HD26825F724E34D17A56762CB48D1EEA3"><enum>(3)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H82590C19FA874679A4C2FC31A24244E9" style="OLC"> <clause id="H9C9CE842A55645E485105D9B36EDE6D0"><enum>(iii)</enum><text display-inline="yes-display-inline">contains an assurance (satisfactory to the Secretary) that the drug for which the application is submitted has not been approved for commercial marketing for any tropical disease indication by a government authority outside of the United States for more than 24 months before the application is submitted;</text></clause><after-quoted-block>.</after-quoted-block></quoted-block>
			</paragraph></section></legis-body>
</bill>


